Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors-Reference-Cited by-同舟云学术

Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors

Published:2006 Issue:9 Volume:107 Page:2291-2297
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Fouladi Maryam,Blaney Susan M.,Poussaint Tina Young,Freeman Burgess B.,McLendon Roger,Fuller Christine,Adesina Adekunle M.,Hancock Michael L.,Danks Mary K.,Stewart Clinton,Boyett James M.,Gajjar Amar

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference44 articles.

1. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

2. Response of recurrent medulloblastoma to low-dose oral etoposide.

3. Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine

4. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine

5. Pattern of recurrence of medulloblastoma after low-dose

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single‐institution study with molecular correlation;Pediatric Blood & Cancer;2024-07-21

2. Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?;Nanomaterials;2023-05-12

3. Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor;Neoplasia;2023-03

4. Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients;Frontiers in Molecular Biosciences;2022-10-14

5. The “SEED” Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors;Frontiers in Bioscience-Landmark;2022-07-12